Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
Rhea-AI Summary
Priovant (NASDAQ: ROIV) announced enrollment of the first patients in BEACON+, a global Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS). The trial will randomize about 140 patients across ~70 sites to brepocitinib 45 mg once daily or placebo (3:2). The primary endpoint is the proportion of patients achieving ≥50% reduction in CSAMI-A at Week 16.
According to Priovant, Phase 2 BEACON showed 77% of brepocitinib 45 mg patients met this endpoint versus 0% on placebo, supporting FDA Breakthrough Therapy Designation in CS. Topline BEACON+ data are expected in 2028. Brepocitinib’s registrational program now spans four orphan indications: dermatomyositis (DM), non-infectious uveitis (NIU), lichen planopilaris (LPP), and CS. The DM NDA is under FDA Priority Review with a PDUFA date later this quarter, and a potential approval and launch are expected by the end of September 2026.
Positive
- Phase 3 BEACON+ initiated in CS with ~140 patients across ~70 sites globally
- Strong Phase 2 CS result: 77% on brepocitinib 45 mg met CSAMI-A ≥50% vs 0% on placebo
- FDA Breakthrough Therapy Designation granted to brepocitinib for cutaneous sarcoidosis
- Brepocitinib program spans four orphan indications with ongoing or completed registrational trials
- Dermatomyositis NDA under FDA Priority Review with a PDUFA date later this quarter
- Potential DM approval and launch expected by end of September 2026, according to Priovant
Negative
- BEACON+ topline data not expected until calendar year 2028, extending the CS development timeline
- No current FDA-approved therapies for cutaneous sarcoidosis despite high disease burden and risk of permanent damage
Market Reaction – ROIV
Following this news, ROIV has gained 1.27%, reflecting a mild positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $35.04.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Trial expansion | Positive | +1.8% | New LPP trial launch accompanied by additional Phase 3 program updates |
| Mar 03 | NDA priority review | Positive | -0.9% | FDA accepted brepocitinib NDA and granted Priority Review in dermatomyositis |
| Feb 06 | Phase 2 results | Positive | +22.1% | Brepocitinib produced statistically significant Phase 2 CS benefit versus placebo |
| Sep 17 | Phase 3 results | Positive | +7.8% | Brepocitinib demonstrated Phase 3 superiority over placebo in dermatomyositis |
| Dec 03 | Trial failure | Negative | -2.9% | Namilumab failed primary and secondary endpoints in pulmonary sarcoidosis |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific clinical-trial events were mostly aligned with same-day price reactions, with one divergence.
Key Terms
breakthrough therapy designation regulatory
nda regulatory
pdufa regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- CS is a highly morbid, chronic, and disfiguring condition with no approved therapies
- Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase 2 BEACON) and has received FDA Breakthrough Therapy Designation for CS
- Global Phase 3 study (BEACON+) is underway, evaluating brepocitinib 45 mg once daily against placebo in 140 patients across approximately 70 sites globally; BEACON+ topline data expected in calendar year 2028
- Brepocitinib’s development program now includes four indications with ongoing or successfully completed registrational trials: dermatomyositis (DM), non-infectious uveitis (NIU), lichen planopilaris (LPP), and CS; potential NDA approval and product launch in DM expected by the end of September 2026
DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Priovant today announced that the first patients have been enrolled in the Phase 3 study evaluating brepocitinib in cutaneous sarcoidosis (CS). This follows brepocitinib’s Phase 2 study, the first positive placebo-controlled study in CS, which led to FDA Breakthrough Therapy Designation.
The Phase 3 study (BEACON+) will be conducted as a Part B to the positive Phase 2 BEACON trial. BEACON+ will enroll approximately 140 patients with cutaneous sarcoidosis across approximately 70 sites globally. Patients will be randomized 3:2 between brepocitinib 45mg once daily and placebo. The primary endpoint is the proportion of patients achieving a
CS is an inflammatory granulomatous skin disease affecting approximately 40,000 adults in the United States. The condition disproportionately impacts Black Americans. Unlike many inflammatory skin diseases, inadequately treated cutaneous sarcoidosis can rapidly cause permanent scarring and destruction of bone, cartilage, and hair follicles. Despite this significant unmet therapeutic need, there are currently no FDA-approved therapies for CS.
“Our vision is to establish brepocitinib as a leading treatment option across multiple rare diseases with high patient burden and few or no alternative therapies,” said Ben Zimmer, Priovant CEO. “The potential upcoming approval and launch of brepocitinib in dermatomyositis later this quarter would be an important milestone toward that vision. We are equally committed to rapidly advancing brepocitinib’s development across multiple additional diseases where patients have a similar urgent need for new treatment options, and the initiation of our CS Phase 3 study reflects that commitment.”
With BEACON+ underway, brepocitinib’s orphan disease development program now includes four indications with ongoing or successfully completed registrational trials. In dermatomyositis (DM), brepocitinib’s NDA is currently under Priority Review with FDA with a PDUFA date later this quarter, following the positive Phase 3 VALOR readout. In non-infectious uveitis (NIU), the Phase 3 CLARITY trial is anticipated to read out later this year. In addition to the Phase 3 BEACON+ study, Priovant is also actively enrolling a Phase 2/3 study evaluating brepocitinib in lichen planopilaris (LPP). All are indications with very high disease burden, risk of permanent organ damage if left untreated, and few or no FDA-approved therapies.
About Priovant
Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a first-in-class, selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib distinctively suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12 and IL-23—with a single, targeted, once-daily oral therapy. Brepocitinib recently generated positive Phase 3 data in dermatomyositis. The New Drug Application for brepocitinib in dermatomyositis is under review at FDA. Brepocitinib is also being evaluated in a Phase 3 program in non-infectious uveitis, a Phase 3 program in cutaneous sarcoidosis, and a Phase 2b/3 program in lichen planopilaris. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.
Contacts:
Stephanie Lee: stephanie.lee@priovant.com
